TY - JOUR

T1 - Potent incretin-based therapy for obesity

T2 - A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety

AU - Müllertz, Alberte Laura Oest

AU - Sandsdal, Rasmus Michael

AU - Jensen, Simon Birk Kjær

AU - Torekov, Signe Sørensen

N1 - Publisher Copyright: © 2024 The Authors. Obesity Reviews published by John Wiley & Sons Ltd on behalf of World Obesity Federation.

PY - 2024

Y1 - 2024

N2 - Potent incretin-based therapy shows promise for the treatment of obesity along with reduced incidence of cardiovascular events in patients with preexisting cardiovascular disease and obesity. This study assessed the efficacy and safety of the incretin-based obesity treatments, once-weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg, in people with obesity without diabetes. Of the 744 records identified, seven randomized controlled trials (n = 5140) were included. Five studies (n = 3288) investigated semaglutide and two studies (n = 1852) investigated tirzepatide. The treatment effect, shown as placebo-subtracted difference, on body weight was −15.0% (95% CI, −17.8 to −12.2) with −12.9% (95% CI, −14.7 to −11.1) for semaglutide and −19.2% (95% CI, −22.2 to −16.2) for tirzepatide. The treatment effect on waist circumference was −11.4 cm (95% CI, −13.7 to −9.2) with −9.7 cm (95% CI, −10.8 to −8.5) for semaglutide and −14.6 cm (95% CI, −15.8 to −13.4) for tirzepatide. The adverse events related to semaglutide and tirzepatide were primarily of mild-to-moderate severity and mostly gastrointestinal, which was more frequent during the dose-titration period and leveled off during the treatment period. This emphasizes that once-weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg induce large reductions in body weight and waist circumference and are generally well-tolerated.

AB - Potent incretin-based therapy shows promise for the treatment of obesity along with reduced incidence of cardiovascular events in patients with preexisting cardiovascular disease and obesity. This study assessed the efficacy and safety of the incretin-based obesity treatments, once-weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg, in people with obesity without diabetes. Of the 744 records identified, seven randomized controlled trials (n = 5140) were included. Five studies (n = 3288) investigated semaglutide and two studies (n = 1852) investigated tirzepatide. The treatment effect, shown as placebo-subtracted difference, on body weight was −15.0% (95% CI, −17.8 to −12.2) with −12.9% (95% CI, −14.7 to −11.1) for semaglutide and −19.2% (95% CI, −22.2 to −16.2) for tirzepatide. The treatment effect on waist circumference was −11.4 cm (95% CI, −13.7 to −9.2) with −9.7 cm (95% CI, −10.8 to −8.5) for semaglutide and −14.6 cm (95% CI, −15.8 to −13.4) for tirzepatide. The adverse events related to semaglutide and tirzepatide were primarily of mild-to-moderate severity and mostly gastrointestinal, which was more frequent during the dose-titration period and leveled off during the treatment period. This emphasizes that once-weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10 or 15 mg induce large reductions in body weight and waist circumference and are generally well-tolerated.

KW - GLP-1

KW - glucagon-like peptide-1 receptor agonist

KW - weight loss

UR - http://www.scopus.com/inward/record.url?scp=85187475929&partnerID=8YFLogxK

U2 - 10.1111/obr.13717

DO - 10.1111/obr.13717

M3 - Review

C2 - 38463003

AN - SCOPUS:85187475929

JO - Obesity Reviews

JF - Obesity Reviews

SN - 1467-7881

ER -